Acquiring Company
ZYMEWORKS
Acquired Company
Theravance Biopharma
Vancouver
DublinBiotechnologyBiotechnologyHealth CareDescription
On September 18, 2026, Theravance Biopharma, Inc. held an Extraordinary General Meeting where shareholders voted on the merger agreement with Zymeworks Inc. This merger aims to combine resources and expertise to enhance their capabilities in the biotechnology sector. The agreement was initially dated June 28, 2026.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment ZYMEWORKS makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Trusted by
Related People
M&A Insights
Based on deal dataFrequently asked
Who acquired Theravance Biopharma?
Theravance Biopharma was acquired by ZYMEWORKS, based in Vancouver. The deal was reported on September 18, 2026. Zymeworks Inc. (Nasdaq: ZYME) is a global biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. ZYMEWORKS is publicly traded (ZYME) and operates in Biotechnology.
When did ZYMEWORKS acquire Theravance Biopharma?
ZYMEWORKS's acquisition of Theravance Biopharma was reported on September 18, 2026. On September 18, 2026, Theravance Biopharma, Inc. held an Extraordinary General Meeting where shareholders voted on the merger agreement with Zymeworks Inc. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Theravance Biopharma do?
Theravance Biopharma, Inc.'s focus is to deliver Medicines that Make a Difference® in people's lives. It is publicly traded (TBPH), operating in Biotechnology, and is based in Dublin.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.
5 screens from a live account. No signup.